Welcome to our dedicated page for Tscan Therapeutics SEC filings (Ticker: TCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
TScan Therapeutics, Inc. filings document the regulatory record for a clinical-stage biotechnology company developing TCR-engineered T cell therapies. Its 8-K filings furnish operating results, corporate presentations, and pipeline disclosures tied to TSC-101, the ALLOHA heme program, CD45-targeted candidates, solid-tumor research, and autoimmunity target discovery.
The company’s filings also cover governance and capital-structure matters, including officer role changes, compensation and retention arrangements, costs associated with portfolio prioritization, and proxy proposals for director elections, auditor ratification, and authorized common stock. The records identify TCRX voting common stock as listed on the Nasdaq Global Market.
TScan Therapeutics granted its Chief Medical Officer, Louis Chrystal, a stock option covering 420,000 shares of voting common stock at an exercise price of $1.12 per share. The option was granted on January 20, 2026 and is held directly. The award vests over four years: 25% of the shares vest on the one-year anniversary of January 20, 2026, with the remaining 75% vesting in equal monthly installments over the following 36 months, conditioned on Chrystal’s continued service with the company on each vesting date.
TScan Therapeutics reported that officer Zoran Zdraveski, Chief Legal and Strategy Officer, received a grant of 350,000 stock options on January 20, 2026. These options give the right to buy TScan voting common stock at an exercise price of $1.12 per share and expire on January 20, 2036.
According to the vesting terms, 25% of the options vest on the one-year anniversary of January 20, 2026, with the remaining options vesting in equal monthly installments over the following 36 months, subject to Mr. Zdraveski’s continued service with the company. After this grant, he beneficially owns 350,000 derivative securities directly in the form of these options.
TScan Therapeutics, Inc. furnished a new corporate presentation that it plans to use in meetings during the 44th Annual J.P. Morgan Healthcare Conference. The materials are provided as Exhibit 99.1 and are also available in the investor relations section of the company’s website. The presentation is being furnished under a current report on Form 8-K, meaning it is not treated as filed for liability purposes and is not automatically incorporated into other securities law filings unless specifically referenced.
TScan Therapeutics, Inc. approved a targeted retention program for key executives tied to progress in its pivotal trial of TSC-101. The Board, following the Compensation Committee’s recommendation, adopted a key employee retention program that provides cash and potential future equity-based awards under the 2021 Equity Incentive Plan.
Under this program, CEO Gavin MacBeath, Ph.D., CFO Jason A. Amello and CMO Chrystal Louis, M.D., M.P.H., will be eligible for cash awards of $399,000, $170,000 and $250,000, respectively. Half of each cash award is payable upon achievement of a milestone related to advancement of the pivotal trial of TSC-101, and the other half on the first anniversary of that milestone.
Upon achievement of the same milestone, they are also slated to receive equity awards of 1,000,000 RSUs, 270,000 RSUs and 650,000 RSUs, respectively. These RSUs are scheduled to vest 25% on the second anniversary of the milestone and 75% upon the earlier of reporting completion of the pivotal TSC-101 trial or the fourth anniversary of the grant date, subject to continued service and the terms of the plan and award agreements.
TScan Therapeutics reported third-quarter results, highlighting collaboration revenue and continued investment in its TCR-T pipeline. Q3 2025 collaboration and license revenue was $2.5 million, while research and development expense reached $31.7 million and general and administrative expense was $7.9 million. The company recorded a net loss of $35.7 million.
As of September 30, 2025, cash, cash equivalents and marketable securities totaled $184.5 million, and long‑term debt was $32.4 million. Year to date, revenue was $7.8 million, primarily from the Amgen collaboration.
After aligning with the FDA on a registrational path for TSC‑101, TScan prioritized its heme program, paused enrollment in its solid tumor Phase 1 trial, and implemented a workforce reduction of approximately 30% (66 roles). The company expects a one‑time charge of up to $2.3 million in Q4 2025 and now expects its cash resources to fund operations into the second half of 2027. As of November 7, 2025, shares outstanding were 52,471,405 voting common and 4,276,588 non‑voting common.
TScan Therapeutics (TCRX) filed an 8-K stating it furnished a press release announcing financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company notes the information is furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless specifically stated.
TScan Therapeutics announced a strategic shift to prioritize its hematologic malignancies program and pause further enrollment in its solid tumor Phase 1 trial. The company will focus preclinical work on in vivo engineering for solid tumors and target discovery in autoimmunity. TScan also implemented a workforce reduction of approximately 30%, or 66 roles, and expects a one-time charge of up to $2.3 million in the quarter ending December 31, 2025.
TScan reported alignment with the FDA on the pivotal study design for TSC-101. The company furnished a press release and slide presentation detailing these updates.
TScan Therapeutics, Inc. furnished an updated corporate presentation that it plans to use in meetings with investors, analysts, and other stakeholders. The presentation reflects revised development and operational milestones, including adjusted timelines for its solid tumor program, updates to its pipeline in both hematologic malignancies and solid tumors, and new information on its target discovery work in autoimmunity.
The presentation is attached as Exhibit 99.1 and is also being made available through the company’s investor relations website, although website materials are not incorporated by reference into this report. The materials are furnished under a regulation disclosure item and are not deemed filed for liability purposes under the securities laws.
Dworak Leiden, reporting as an officer (Principal Accounting Officer) of TScan Therapeutics, Inc. (TCRX), filed an initial Form 3 reporting ownership of stock options granted by the company. The Form 3 reflects six option grants exercisable between 04/03/2032 and 01/02/2035 covering a total of 366,925 shares of Voting Common Stock with exercise prices ranging from $1.81 to $6.00. Vesting schedules are described for each grant, generally providing 25% vesting after one year followed by equal monthly vesting over 36 months, with certain tranches tied to service dates or shareholder approval. The filing date for the event is 08/14/2025 and the Form is signed by an attorney-in-fact on behalf of the reporting person.
TScan Therapeutics, Inc. reported a leadership change in its finance organization. On August 14, 2025, the Board appointed Leiden Dworak, the company’s Vice President of Finance, as Principal Accounting Officer, effective the same day. Jason A. Amello ceased serving in that accounting role but continues as Chief Financial Officer and Principal Financial Officer.
Mr. Dworak, age 41, has been Vice President, Finance since April 2022 and previously served as the company’s Principal Accounting Officer from July 2023 to January 2024. He brings 17 years of finance experience in biotechnology and life sciences, including roles at AVROBIO, Moderna, Merrimack Pharmaceuticals, SeraCare Life Sciences, and Boston Scientific, and holds an MBA from Indiana University. The company states there are no family relationships or related party transactions requiring disclosure in connection with this appointment.